Current tau monoclonal antibody targets include N-terminal, mid-domain regions, and specific phosphorylated epitopes in NFTs. However, the only currently published clinical trial results for a monoclonal antibody targeting tau come from antibodies against the N-terminal region, and no long-term data on efficacy have yet been published. Many tau epitope targets remain unexplored.
